Protective effects of cilazapril against free radical injury in myocardial ischaemia-reperfusion.
Cilazapril is a prodrug which is rapidly hydrolysed to the pharmacologically active cilazaprilat following absorption to the bloodstream. In clinical pharmacological studies, administration of cilazapril resulted in potent, reversible, selective and competitive angiotensin converting enzyme inhibition. In this study, we have examined the protective effect of cilazapril on a myocardial ischaemia-reperfusion model by using different parameters of lipid peroxidation and protein oxidation. We have observed increased levels of diene conjugates, carbonyls and malondialdehyde as well as protein carbonyls after ischaemia-reperfusion, whereas protein sulphydryl groups were decreased. Our results clearly demonstrate that cilazapril, a non-sulphydryl, long-acting angiotensin converting enzyme inhibitor, has free-radical-scavenging potential in a model comparable to the clinical situation observed in humans.
Haklar
G
G
Department of Biochemistry, Faculty of Medicine, Marmara University, Haydarpaşa-Istanbul, Turkey.
Erşahin
C
C
Moini
H
H
Süngün
M
M
Dogan
N
N
Bilsel
S
S
Emerk
K
K
Yalçin
A S
AS
D000818:Animals; D017315:Cilazapril / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D016166:Free Radical Scavengers / Q000494:pharmacology / Q000627:therapeutic use; D005609:Free Radicals / Q000009:adverse effects / Q000378:metabolism; D006801:Humans; D050356:Lipid Metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D009200:Myocardial Contraction; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000378:metabolism; D015428:Myocardial Reperfusion Injury / Q000378:metabolism / Q000517:prevention & control*; D009206:Myocardium / Q000378:metabolism; D011506:Proteins / Q000378:metabolism; D011817:Rabbits
D016166:Free Radical Scavengers; D005609:Free Radicals; D011506:Proteins; D017315:Cilazapril